Insider Transactions in Q1 2024 at Acelrx Pharmaceuticals Inc (ACRX)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 15
2024
|
Nantahala Capital Management, LLC > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
755,000
+27.48%
|
$3,775,000
$5.0 P/Share
|
|
Mar 12
2024
|
Vincent J. Angotti CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+4.47%
|
$8,000
$1.12 P/Share
|
|
Mar 11
2024
|
Vincent J. Angotti CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+0.61%
|
$1,000
$1.12 P/Share
|
|
Mar 03
2024
|
Pamela P Palmer Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
450
-0.76%
|
$450
$1.3 P/Share
|
|
Mar 03
2024
|
Badri N Dasu Chief Engineering Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
406
-1.28%
|
$406
$1.3 P/Share
|
|
Mar 03
2024
|
Vincent J. Angotti CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,623
-0.99%
|
$1,623
$1.3 P/Share
|
|
Mar 03
2024
|
Raffi Asadorian Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
558
-1.46%
|
$558
$1.3 P/Share
|
|
Feb 14
2024
|
Pamela P Palmer Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,000
+25.23%
|
-
|
|
Feb 14
2024
|
Raffi Asadorian Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,000
+31.98%
|
-
|
|
Feb 14
2024
|
Badri N Dasu Chief Engineering Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,667
+31.55%
|
-
|
|
Feb 14
2024
|
Vincent J. Angotti CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
58,667
+27.66%
|
-
|
|
Feb 11
2024
|
Pamela P Palmer Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
801
-2.22%
|
$801
$1.1 P/Share
|
|
Feb 11
2024
|
Badri N Dasu Chief Engineering Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
809
-4.5%
|
$809
$1.1 P/Share
|
|
Feb 11
2024
|
Vincent J. Angotti CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,723
-3.78%
|
$3,723
$1.1 P/Share
|
|
Feb 11
2024
|
Raffi Asadorian Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
895
-4.22%
|
$895
$1.1 P/Share
|
|
Feb 10
2024
|
Pamela P Palmer Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
801
-2.17%
|
$801
$1.1 P/Share
|
|
Feb 10
2024
|
Badri N Dasu Chief Engineering Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
809
-4.31%
|
$809
$1.1 P/Share
|
|
Feb 10
2024
|
Vincent J. Angotti CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,320
-3.26%
|
$3,320
$1.1 P/Share
|
|
Feb 10
2024
|
Raffi Asadorian Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
895
-4.05%
|
$895
$1.1 P/Share
|
|
Jan 22
2024
|
Abhinav Jain |
BUY
Grant, award, or other acquisition
|
Direct |
871
+50.0%
|
-
|